Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RGC – Regencell Bioscience Holdings Ltd

RGC — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

1.38

Margin Of Safety %

Put/Call OI Ratio

0.84

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

28.5

Target Price

Analyst Recom

Performance Q

-8.46

Upside

-100.5%

Beta

1.73

Ticker: RGC



22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-16RGC30.451.080.266543
2026-04-17RGC28.571.100.606606
2026-04-20RGC281.740.313453
2026-04-21RGC28.151.800.123433
2026-04-22RGC29.271.350.373930
2026-04-23RGC28.491.150.274707
2026-04-24RGC27.411.250.454635
2026-04-27RGC29.121.030.095292
2026-04-28RGC28.861.020.535359
2026-04-29RGC28.890.990.925456
2026-04-30RGC29.361.090.035557
2026-05-01RGC29.071.050.135655
2026-05-04RGC27.251.050.045693
2026-05-05RGC27.21.130.655515
2026-05-06RGC27.561.131.735548
2026-05-07RGC31.761.230.165657
2026-05-08RGC29.51.040.036162
2026-05-11RGC27.350.910.196604
2026-05-12RGC27.030.830.587119
2026-05-13RGC27.420.880.057064
2026-05-14RGC27.1650.830.187278
2026-05-15RGC28.50.840.177334
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-16RGC30.43- - -
2026-04-17RGC28.77- - -
2026-04-20RGC28.10- - -
2026-04-21RGC28.17- - -
2026-04-22RGC29.38- - -
2026-04-23RGC28.36- - -
2026-04-24RGC27.42- - -
2026-04-27RGC29.23- - -
2026-04-28RGC29.00- - -
2026-04-29RGC29.00- - -
2026-04-30RGC29.47- - -
2026-05-01RGC29.09- - -
2026-05-04RGC27.30- - -
2026-05-05RGC27.27- - -
2026-05-06RGC27.57- - -
2026-05-07RGC31.87- - -
2026-05-08RGC29.30- - -
2026-05-11RGC27.35- - -
2026-05-12RGC27.28- - -
2026-05-13RGC27.24- - -
2026-05-14RGC27.04- - -
2026-05-15RGC28.50- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-17RGC0.00-7.581.24
2026-04-20RGC0.00-7.491.24
2026-04-21RGC0.00-7.491.24
2026-04-22RGC0.00-7.491.25
2026-04-23RGC0.00-7.491.25
2026-04-24RGC0.00-7.491.25
2026-04-27RGC0.00-7.461.48
2026-04-28RGC0.00-7.461.48
2026-04-29RGC0.00-7.461.48
2026-04-30RGC0.00-7.461.48
2026-05-01RGC0.00-7.461.48
2026-05-04RGC0.00-7.461.48
2026-05-05RGC0.00-7.461.48
2026-05-06RGC0.00-7.461.48
2026-05-07RGC0.00-7.461.48
2026-05-08RGC0.00-7.461.48
2026-05-11RGC0.00-7.461.48
2026-05-12RGC0.00-7.461.38
2026-05-13RGC0.00-7.461.38
2026-05-14RGC0.00-7.461.38
2026-05-15RGC0.00-7.461.38
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-7.46

Beta

1.73

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

4

Growth Score

Sentiment Score

19

Actual DrawDown %

97

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

11570.85

P/Free Cash Flow

EPS

-0.01

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.88

Return on Equity vs Sector %

-605

Return on Equity vs Industry %

-586.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ RGC Healthcare
$28.58
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
12/20
Pullback
9/25
Volume
7/15
Valuation
6/20
TP/AR
2/10
Options
5/10
RSI
51.3
Range 1M
50.9%
Sup Dist
8.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
18 /100
WEAK
Momentum
5/25
Growth
7/30
Estimates
0/20
Inst/Vol
1/15
Options
5/10
EPS Yr
0%
EPS NY
0%
52W%
27.6%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
Quality
2/30
Valuation
2/30
Growth
3/25
Stability
4/10
LT Trend
4/5
Quality
4
Click a card to see score breakdown Full Analysis →
Regencell Bioscience Holdings L
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 10
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
RGC

Latest News

—
Caricamento notizie per RGC…
stock quote shares RGC – Regencell Bioscience Holdings Ltd Stock Price stock today
news today RGC – Regencell Bioscience Holdings Ltd stock forecast ,stock prediction 2023 2024 2025
marketwatch RGC – Regencell Bioscience Holdings Ltd yahoo finance google finance
stock history RGC – Regencell Bioscience Holdings Ltd invest stock market
stock prices RGC premarket after hours
ticker RGC fair value insiders trading

TXMD – TherapeuticsMD Inc.

TXMD — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.53

Margin Of Safety %

-23

Put/Call OI Ratio

0.03

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

2.01

Target Price

5

Analyst Recom

3

Performance Q

-15.25

Upside

-87.0%

Beta

0.58

Ticker: TXMD



22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-16TXMD2.090.030.001220
2026-04-17TXMD2.080.030.001220
2026-04-20TXMD2.090.030.001220
2026-04-21TXMD2.240.030.001220
2026-04-22TXMD2.140.030.001220
2026-04-23TXMD2.170.030.001220
2026-04-24TXMD2.2N/AN/A0
2026-04-27TXMD2.160.030.001169
2026-04-28TXMD2.130.030.001229
2026-04-29TXMD2.070.030.001229
2026-04-30TXMD2.080.030.001229
2026-05-01TXMD2.040.03999.991229
2026-05-04TXMD2.030.03999.991229
2026-05-05TXMD2.010.03999.991229
2026-05-06TXMD2.080.03999.991229
2026-05-07TXMD2.010.03999.991229
2026-05-08TXMD2.030.03999.991208
2026-05-11TXMD1.970.03999.991208
2026-05-12TXMD1.98930.03999.991208
2026-05-13TXMD2.060.03999.991208
2026-05-14TXMD2.020.03999.991208
2026-05-15TXMD2.020.03999.991206
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-16TXMD2.03- - -
2026-04-17TXMD2.04- - -
2026-04-20TXMD2.17- - -
2026-04-21TXMD2.24- - -
2026-04-22TXMD2.18- - -
2026-04-23TXMD2.18- - -
2026-04-24TXMD2.20- - -
2026-04-27TXMD2.08- - -
2026-04-28TXMD2.16- - -
2026-04-29TXMD2.04- - -
2026-04-30TXMD2.09- - -
2026-05-01TXMD2.05- - -
2026-05-04TXMD2.03- - -
2026-05-05TXMD2.06- - -
2026-05-06TXMD2.08- - -
2026-05-07TXMD2.00- - -
2026-05-08TXMD2.01- - -
2026-05-11TXMD1.97- - -
2026-05-12TXMD1.97- - -
2026-05-13TXMD2.05- - -
2026-05-14TXMD2.03- - -
2026-05-15TXMD2.01- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-16TXMD4.696.910.42
2026-04-17TXMD4.696.910.42
2026-04-20TXMD4.696.910.42
2026-04-21TXMD4.696.910.42
2026-04-22TXMD4.696.910.45
2026-04-23TXMD1.076.910.45
2026-04-24TXMD1.076.910.45
2026-04-27TXMD1.076.910.48
2026-04-28TXMD1.076.910.48
2026-04-29TXMD1.076.910.48
2026-04-30TXMD1.076.910.48
2026-05-01TXMD1.076.910.48
2026-05-04TXMD1.076.910.48
2026-05-05TXMD1.076.910.48
2026-05-06TXMD1.076.910.48
2026-05-07TXMD1.076.910.48
2026-05-08TXMD1.076.910.48
2026-05-11TXMD1.077.120.48
2026-05-12TXMD1.077.120.53
2026-05-13TXMD1.077.120.53
2026-05-14TXMD1.077.120.53
2026-05-15TXMD1.077.120.53
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

1.07

Institutional Transactions

7.12

Beta

0.58

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

1.54

Quality Score

37

Growth Score

40

Sentiment Score

63

Actual DrawDown %

97.1

Max Drawdown 5-Year %

-99

Target Price

5

P/E

129.87

Forward P/E

PEG

P/S

6.91

P/B

0.86

P/Free Cash Flow

8.67

EPS

0.02

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.34

Relative Volume

0.43

Return on Equity vs Sector %

-26.3

Return on Equity vs Industry %

-7.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ TXMD Healthcare
$2.00
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
6/20
Pullback
19/25
Volume
11/15
Valuation
12/20
TP/AR
0/10
Options
6/10
RSI
44.4
Range 1M
24.2%
Sup Dist
1.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
22 /100
WEAK
Momentum
1/25
Growth
7/30
Estimates
1/20
Inst/Vol
6/15
Options
7/10
EPS Yr
0%
EPS NY
0%
52W%
51.8%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +46.2% upside
Quality
5/30
Valuation
15/30
Growth
5/25
Stability
7/10
LT Trend
2/5
Upside
+46.2%
Quality
37
MoS
-23%
Click a card to see score breakdown Full Analysis →
TherapeuticsMD, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
TXMD

Latest News

—
Caricamento notizie per TXMD…
stock quote shares TXMD – TherapeuticsMD Inc. Stock Price stock today
news today TXMD – TherapeuticsMD Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch TXMD – TherapeuticsMD Inc. yahoo finance google finance
stock history TXMD – TherapeuticsMD Inc. invest stock market
stock prices TXMD premarket after hours
ticker TXMD fair value insiders trading

EVO – Evotec SE

EVO — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.03

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-0.36

EPS This/Next Y

0.54

Price

2.68

Target Price

3.99

Analyst Recom

2.2

Performance Q

-23.08

Upside

-916.7%

Beta

1.92

Ticker: EVO



22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-16EVO3.22N/AN/A0
2026-04-17EVO3.26N/AN/A0
2026-04-20EVO3.16N/AN/A0
2026-04-21EVO3.24N/AN/A0
2026-04-22EVO3.3N/AN/A0
2026-04-23EVO3.22N/AN/A0
2026-04-24EVO3.15N/AN/A0
2026-04-27EVO3.13N/AN/A0
2026-04-28EVO3N/AN/A0
2026-04-29EVO2.93N/AN/A0
2026-04-30EVO3.1N/AN/A0
2026-05-01EVO3.1N/AN/A0
2026-05-04EVO3.13N/AN/A0
2026-05-05EVO3.14N/AN/A0
2026-05-06EVO3.23N/AN/A0
2026-05-07EVO3.06N/AN/A0
2026-05-08EVO3.08N/AN/A0
2026-05-11EVO3.05N/AN/A0
2026-05-12EVO2.98N/AN/A0
2026-05-13EVO2.72N/AN/A0
2026-05-14EVO2.73N/AN/A0
2026-05-15EVO2.68N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-16EVO3.21- 54.6-0.37
2026-04-17EVO3.25- 51.6-0.26
2026-04-20EVO3.15- 52.5-0.26
2026-04-21EVO3.24- 51.6-0.26
2026-04-22EVO3.30- 9.2-0.26
2026-04-23EVO3.23- 11.2-0.26
2026-04-24EVO3.15- 9.3-0.26
2026-04-27EVO3.13- 9.0-0.26
2026-04-28EVO3.00- 11.7-0.26
2026-04-29EVO2.93- 11.1-0.26
2026-04-30EVO3.10- 4.5-0.26
2026-05-01EVO3.10- 8.3-0.26
2026-05-04EVO3.12- 9.8-0.26
2026-05-05EVO3.15- 11.0-0.26
2026-05-06EVO3.23- 9.7-0.26
2026-05-07EVO3.06- -1.7-0.26
2026-05-08EVO3.08- 104.6-0.26
2026-05-11EVO3.06- 103.7-0.26
2026-05-12EVO3.00- 106.9-0.70
2026-05-13EVO2.71- 113.8-0.70
2026-05-14EVO2.73- 102.9-0.70
2026-05-15EVO2.68- 108.0-0.70
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-17EVO0.00-2.920.10
2026-04-20EVO0.00-3.230.10
2026-04-21EVO0.00-3.230.10
2026-04-22EVO0.00-3.230.10
2026-04-23EVO0.00-3.230.10
2026-04-24EVO0.00-3.230.10
2026-04-27EVO0.00-54.860.12
2026-04-28EVO0.00-54.860.12
2026-04-29EVO0.00-54.860.12
2026-04-30EVO0.00-54.860.12
2026-05-01EVO0.00-54.860.12
2026-05-04EVO0.00-47.790.12
2026-05-05EVO0.00-47.790.12
2026-05-06EVO0.00-47.790.12
2026-05-07EVO0.00-47.790.12
2026-05-08EVO0.00-47.790.12
2026-05-11EVO0.00-46.060.12
2026-05-12EVO0.00-46.060.03
2026-05-13EVO0.00-46.060.03
2026-05-14EVO0.00-46.060.03
2026-05-15EVO0.00-46.060.03
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

0.09

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

Institutional Transactions

-46.06

Beta

1.92

Average Sales Estimate Current Quarter

169

Average Sales Estimate Next Quarter

184

Fair Value

Quality Score

34

Growth Score

33

Sentiment Score

37

Actual DrawDown %

89.9

Max Drawdown 5-Year %

-91.3

Target Price

3.99

P/E

Forward P/E

PEG

P/S

1.11

P/B

1.19

P/Free Cash Flow

EPS

-0.63

Average EPS Est. Cur. Y​

-0.7

EPS Next Y. (Est.)

-0.16

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.08

Relative Volume

0.36

Return on Equity vs Sector %

-54.6

Return on Equity vs Industry %

-35.7

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.35

EBIT Estimation

108
◆ EVO Healthcare
$2.70
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
10/20
Pullback
23/25
Volume
11/15
Valuation
12/20
TP/AR
1/10
Options
0/10
RSI
37.2
Range 1M
7.4%
Sup Dist
0.4%
🚀
Momentum Growth
Ride accelerating trends
N/A
12 /100
WEAK
Momentum
4/25
Growth
8/30
Estimates
0/20
Inst/Vol
0/15
Options
0/10
EPS Yr
-15.7%
EPS NY
82.9%
52W%
15.3%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +47.8% upside
Quality
2/30
Valuation
12/30
Growth
6/25
Stability
4/10
LT Trend
4/5
Upside
+47.8%
Quality
34
Click a card to see score breakdown Full Analysis →
Evotec SE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 4526
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
EVO

Latest News

—
Caricamento notizie per EVO…
stock quote shares EVO – Evotec SE Stock Price stock today
news today EVO – Evotec SE stock forecast ,stock prediction 2023 2024 2025
marketwatch EVO – Evotec SE yahoo finance google finance
stock history EVO – Evotec SE invest stock market
stock prices EVO premarket after hours
ticker EVO fair value insiders trading

EOLS – Evolent Health Inc.

EOLS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

13.75

Margin Of Safety %

Put/Call OI Ratio

0.29

EPS Next Q Diff

0.09

EPS Last/This Y

0.68

EPS This/Next Y

0.39

Price

6.49

Target Price

14.67

Analyst Recom

1.29

Performance Q

51.16

Upside

-460.8%

Beta

1.34

Ticker: EOLS



22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-16EOLS4.530.350.7215037
2026-04-17EOLS4.680.332.1914867
2026-04-20EOLS5.080.440.3910943
2026-04-21EOLS4.930.410.2011300
2026-04-22EOLS5.20.410.0211339
2026-04-23EOLS5.310.400.0711457
2026-04-24EOLS5.30.400.0011562
2026-04-27EOLS5.230.390.0011616
2026-04-28EOLS5.280.390.0311640
2026-04-29EOLS5.190.390.2711656
2026-04-30EOLS5.40.390.0611796
2026-05-01EOLS5.320.390.6111777
2026-05-04EOLS5.560.380.0111754
2026-05-05EOLS6.370.270.0615166
2026-05-06EOLS6.320.290.0414552
2026-05-07EOLS6.40.290.0014530
2026-05-08EOLS6.370.3071.6714385
2026-05-11EOLS6.320.300.4314424
2026-05-12EOLS6.510.300.0014427
2026-05-13EOLS6.720.300.0014437
2026-05-14EOLS6.590.290.0014792
2026-05-15EOLS6.490.290.0014799
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-16EOLS4.5330.912.3-0.12
2026-04-17EOLS4.6930.911.5-0.12
2026-04-20EOLS5.0930.910.7-0.12
2026-04-21EOLS4.9330.912.4-0.12
2026-04-22EOLS5.2030.911.2-0.12
2026-04-23EOLS5.3230.911.6-0.12
2026-04-24EOLS5.3130.912.1-0.12
2026-04-27EOLS5.2430.912.2-0.12
2026-04-28EOLS5.2830.911.8-0.12
2026-04-29EOLS5.1930.912.2-0.12
2026-04-30EOLS5.4030.911.4-0.12
2026-05-01EOLS5.3230.912.2-0.12
2026-05-04EOLS5.6030.911.2-0.12
2026-05-05EOLS6.3630.99.9-0.12
2026-05-06EOLS6.3230.912.1-0.12
2026-05-07EOLS6.4030.911.9-0.12
2026-05-08EOLS6.3830.912.0-0.11
2026-05-11EOLS6.3280.512.0-0.12
2026-05-12EOLS6.5176.610.4-0.12
2026-05-13EOLS6.7276.610.4-0.12
2026-05-14EOLS6.5976.610.9-0.12
2026-05-15EOLS6.4976.610.9-0.12
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-16EOLS-1.14-9.0813.08
2026-04-17EOLS-1.14-9.0813.08
2026-04-20EOLS-1.14-9.0813.08
2026-04-21EOLS-1.14-9.0813.08
2026-04-22EOLS-1.14-9.0813.08
2026-04-23EOLS-1.14-9.0813.08
2026-04-24EOLS-1.14-9.0813.08
2026-04-27EOLS-1.14-8.1613.83
2026-04-28EOLS-1.01-8.1613.83
2026-04-29EOLS-1.01-8.1613.83
2026-04-30EOLS-1.01-8.1613.83
2026-05-01EOLS-1.01-8.1613.83
2026-05-04EOLS-1.01-8.1313.83
2026-05-05EOLS-1.01-8.1313.83
2026-05-06EOLS-1.01-8.1313.83
2026-05-07EOLS-1.00-8.1313.66
2026-05-08EOLS-1.00-8.1313.66
2026-05-11EOLS-1.00-8.1813.66
2026-05-12EOLS-1.00-8.1813.75
2026-05-13EOLS-1.00-8.1813.75
2026-05-14EOLS-1.00-8.1813.75
2026-05-15EOLS-1.00-8.1813.75
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS​

-0.16

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

-1

Institutional Transactions

-8.18

Beta

1.34

Average Sales Estimate Current Quarter

81

Average Sales Estimate Next Quarter

78

Fair Value

Quality Score

36

Growth Score

48

Sentiment Score

55

Actual DrawDown %

63.6

Max Drawdown 5-Year %

-77.5

Target Price

14.67

P/E

Forward P/E

24.37

PEG

P/S

1.42

P/B

P/Free Cash Flow

EPS

-0.67

Average EPS Est. Cur. Y​

-0.12

EPS Next Y. (Est.)

0.27

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14.39

Relative Volume

0.51

Return on Equity vs Sector %

123.9

Return on Equity vs Industry %

142.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

10.9
◆ EOLS Healthcare
$6.50
📉
Swing / Pullback
Buy the dip on strong trends
46 /100
WEAK
Trend
2/20
Pullback
8/25
Volume
11/15
Valuation
15/20
TP/AR
2/10
Options
8/10
RSI
71
Range 1M
89.8%
Sup Dist
0.2%
🚀
Momentum Growth
Ride accelerating trends
43 /100
WEAK
Momentum
9/25
Growth
24/30
Estimates
1/20
Inst/Vol
3/15
Options
6/10
EPS Yr
78.6%
EPS NY
383.7%
52W%
39.4%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +68.3% upside
Quality
7/30
Valuation
14/30
Growth
16/25
Stability
7/10
LT Trend
1/5
Upside
+68.3%
Quality
36
Click a card to see score breakdown Full Analysis →
Evolus, Inc. Common Stock
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 350
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS

Latest News

—
Caricamento notizie per EOLS…
stock quote shares EOLS – Evolent Health Inc. Stock Price stock today
news today EOLS – Evolent Health Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EOLS – Evolent Health Inc. yahoo finance google finance
stock history EOLS – Evolent Health Inc. invest stock market
stock prices EOLS premarket after hours
ticker EOLS fair value insiders trading

AYTU – Aytu BioPharma Inc.

AYTU — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

5.17

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.22

EPS Last/This Y

0.92

EPS This/Next Y

1.19

Price

2.18

Target Price

9.33

Analyst Recom

1

Performance Q

2.82

Upside

-7,419.6%

Beta

0.25

Ticker: AYTU



22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-16AYTU2.56N/AN/A0
2026-04-17AYTU2.6N/AN/A0
2026-04-20AYTU2.63N/AN/A0
2026-04-21AYTU2.48N/AN/A0
2026-04-22AYTU2.57N/AN/A0
2026-04-23AYTU2.51N/AN/A0
2026-04-24AYTU2.56N/AN/A0
2026-04-27AYTU2.6N/AN/A0
2026-04-28AYTU2.55N/AN/A0
2026-04-29AYTU2.52N/AN/A0
2026-04-30AYTU2.58N/AN/A0
2026-05-01AYTU2.625N/AN/A0
2026-05-04AYTU2.56N/AN/A0
2026-05-05AYTU2.615N/AN/A0
2026-05-06AYTU2.57N/AN/A0
2026-05-07AYTU2.51N/AN/A0
2026-05-08AYTU2.49N/AN/A0
2026-05-11AYTU2.44N/AN/A0
2026-05-12AYTU2.3N/AN/A0
2026-05-13AYTU2.25N/AN/A0
2026-05-14AYTU2.2668N/AN/A0
2026-05-15AYTU2.18N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-16AYTU2.54- - -1.47
2026-04-17AYTU2.64- - -1.47
2026-04-20AYTU2.62- - -1.47
2026-04-21AYTU2.52- - -1.47
2026-04-22AYTU2.58- - -1.47
2026-04-23AYTU2.52- - -1.47
2026-04-24AYTU2.55- - -1.24
2026-04-27AYTU2.56- - -1.24
2026-04-28AYTU2.53- - -1.24
2026-04-29AYTU2.53- - -1.24
2026-04-30AYTU2.57- - -1.24
2026-05-01AYTU2.61- - -1.24
2026-05-04AYTU2.56- - -1.24
2026-05-05AYTU2.59- - -1.24
2026-05-06AYTU2.55- - -1.24
2026-05-07AYTU2.48- - -1.24
2026-05-08AYTU2.49- - -1.24
2026-05-11AYTU2.44- - -1.24
2026-05-12AYTU2.30- - -1.24
2026-05-13AYTU2.25- - -1.24
2026-05-14AYTU2.26- - -1.24
2026-05-15AYTU2.18- - -1.24
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-16AYTU0.0010.635.18
2026-04-17AYTU0.0010.635.18
2026-04-20AYTU0.0010.485.18
2026-04-21AYTU0.0010.485.18
2026-04-22AYTU0.0010.485.15
2026-04-23AYTU0.0010.485.15
2026-04-24AYTU0.0010.485.15
2026-04-27AYTU0.009.575.14
2026-04-28AYTU0.009.575.14
2026-04-29AYTU0.009.575.14
2026-04-30AYTU0.009.575.14
2026-05-01AYTU0.009.575.14
2026-05-04AYTU0.009.195.14
2026-05-05AYTU0.009.195.14
2026-05-06AYTU0.009.195.14
2026-05-07AYTU0.009.195.14
2026-05-08AYTU0.009.195.14
2026-05-11AYTU0.008.895.14
2026-05-12AYTU0.008.895.17
2026-05-13AYTU0.008.895.17
2026-05-14AYTU0.008.895.17
2026-05-15AYTU0.008.895.17
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS​

-0.53

Avg. EPS Est. Current Quarter

-0.61

Avg. EPS Est. Next Quarter

-0.3

Insider Transactions

Institutional Transactions

8.89

Beta

0.25

Average Sales Estimate Current Quarter

13

Average Sales Estimate Next Quarter

12

Fair Value

Quality Score

38

Growth Score

33

Sentiment Score

47

Actual DrawDown %

98.2

Max Drawdown 5-Year %

-99.1

Target Price

9.33

P/E

Forward P/E

PEG

P/S

0.42

P/B

0.67

P/Free Cash Flow

14.33

EPS

-4.58

Average EPS Est. Cur. Y​

-1.24

EPS Next Y. (Est.)

-0.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-60.17

Relative Volume

1.73

Return on Equity vs Sector %

-123.8

Return on Equity vs Industry %

-104.9

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.23

EBIT Estimation

◆ AYTU Healthcare
$2.19
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
9/25
Volume
3/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
28.4
Range 1M
5.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
42 /100
WEAK
Momentum
14/25
Growth
19/30
Estimates
0/20
Inst/Vol
9/15
Options
0/10
EPS Yr
53.7%
EPS NY
94%
52W%
45.2%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +326% upside
Quality
6/30
Valuation
16/30
Growth
13/25
Stability
4/10
LT Trend
3/5
Upside
+326%
Quality
38
Click a card to see score breakdown Full Analysis →
Aytu BioPharma, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 82
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
AYTU

Latest News

—
Caricamento notizie per AYTU…
stock quote shares AYTU – Aytu BioPharma Inc. Stock Price stock today
news today AYTU – Aytu BioPharma Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AYTU – Aytu BioPharma Inc. yahoo finance google finance
stock history AYTU – Aytu BioPharma Inc. invest stock market
stock prices AYTU premarket after hours
ticker AYTU fair value insiders trading